ALLMedicine™ Pneumocystis Jiroveci Pneumonia (PJP) Center
Research & Reviews 49 results
https://doi.org/10.1111/jcpt.13213
Journal of Clinical Pharmacy and Therapeutics REFERENCES; Yu Y, Yang H et. al.
Jul 27th, 2020 - Pneumocystis jiroveci (P jiroveci) is an important opportunistic fungus and causes pneumocystis jiroveci pneumonia (PJP) in kidney transplant recipients (KTRs). By using the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument...
https://doi.org/10.1055/s-0039-3399559
Seminars in Respiratory and Critical Care Medicine; Fishman JA
Jan 30th, 2020 - Pneumocystis jiroveci remains an important fungal pathogen in a broad range of immunocompromised hosts. The natural reservoir of infection remains unknown. Pneumocystis jiroveci Pneumonia (PJP) develops via airborne transmission or reactivation of...
https://www.mdedge.com/chestphysician/article/210199/cll/pjp-prophylaxis-may-be-unnecessary-cll-patients-btk-inhibitors?channel=234
Sharon Worcester, MDedge News
Oct 16th, 2019 - EDINBURGH – Routine empiric prophylaxis against pneumocystis jiroveci pneumonia (PJP) may be unwarranted in chronic lymphocytic leukemia patients initiating Bruton tyrosine kinase (BTK) inhibitor therapy, a retrospective chart review suggests. Dr.
https://doi.org/10.1111/tid.13191
Transplant Infectious Disease : an Official Journal of Th... Pryor JB, Olyaei AJ et. al.
Oct 9th, 2019 - Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line agent for Pneumocystis jiroveci pneumonia (PJP) prophylaxis for solid organ transplant (SOT) recipients because of its efficacy for this indication, extended antimicrobial coverage, and fav...
https://emedicine.medscape.com/article/225976-overview
Apr 23rd, 2019 - Overview of Pneumocystis jiroveci Pneumonia Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP), is the most common opportunistic infection in persons with HIV infection. Pneumocystis first came to attenti...
Drugs 2 results see all →
Clinicaltrials.gov 53 results
https://doi.org/10.1111/jcpt.13213
Journal of Clinical Pharmacy and Therapeutics REFERENCES; Yu Y, Yang H et. al.
Jul 27th, 2020 - Pneumocystis jiroveci (P jiroveci) is an important opportunistic fungus and causes pneumocystis jiroveci pneumonia (PJP) in kidney transplant recipients (KTRs). By using the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument...
https://doi.org/10.1055/s-0039-3399559
Seminars in Respiratory and Critical Care Medicine; Fishman JA
Jan 30th, 2020 - Pneumocystis jiroveci remains an important fungal pathogen in a broad range of immunocompromised hosts. The natural reservoir of infection remains unknown. Pneumocystis jiroveci Pneumonia (PJP) develops via airborne transmission or reactivation of...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb
Jan 22nd, 2020 - NebuPent is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4+ (T4 helper/in...
https://www.mdedge.com/chestphysician/article/210199/cll/pjp-prophylaxis-may-be-unnecessary-cll-patients-btk-inhibitors?channel=234
Sharon Worcester, MDedge News
Oct 16th, 2019 - EDINBURGH – Routine empiric prophylaxis against pneumocystis jiroveci pneumonia (PJP) may be unwarranted in chronic lymphocytic leukemia patients initiating Bruton tyrosine kinase (BTK) inhibitor therapy, a retrospective chart review suggests. Dr.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c484f16e-9d97-4416-84a4-8ad8deaf5e19
Oct 10th, 2019 - Pentamidine Isethionate is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4...
News 1 results
https://www.mdedge.com/chestphysician/article/210199/cll/pjp-prophylaxis-may-be-unnecessary-cll-patients-btk-inhibitors?channel=234
Sharon Worcester, MDedge News
Oct 16th, 2019 - EDINBURGH – Routine empiric prophylaxis against pneumocystis jiroveci pneumonia (PJP) may be unwarranted in chronic lymphocytic leukemia patients initiating Bruton tyrosine kinase (BTK) inhibitor therapy, a retrospective chart review suggests. Dr.